# Catheter Precision, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Catheter Precision, Inc.).

## Overview

Catheter Precision, Inc. develops and commercializes medical devices for cardiac electrophysiology and wound closure. Its current business is centered on two products: the VIVO System, which helps localize the origin of idiopathic ventricular arrhythmias, and LockeT, a suture retention device used to support wound healing. The company also has a history of technology development outside its current focus, including prior work on an excimer laser platform and more recently intellectual property related to cardiac-device interfacing. Catheter Precision sells through distributors and direct international relationships, with a meaningful portion of sales coming from outside the United States. The business remains early-stage and capital constrained, with recurring operating losses and a focus on product commercialization and regulatory expansion.

## Products & services

• VIVO System for 3D cardiac mapping
• LockeT suture retention device
• Software upgrade services for VIVO
• International distributor sales and support
• CE Mark and FDA-regulated medical device commercialization

- **Cardiac electrophysiology mapping** (60%) — 3D mapping and localization tools used by electrophysiologists to identify arrhythmia origin sites before procedures.
- **Surgical wound closure support** (30%) — Suture retention devices used to distribute tension and support wound healing during closure.
- **Software and service upgrades** (5%) — Optional software upgrades and related support services sold with the VIVO System.
- **International distribution and regulatory commercialization** (5%) — Commercial activity tied to distributor channels, CE Mark expansion, and market access work.

- VIVO System for 3D cardiac mapping
- LockeT suture retention device
- Software upgrade services for VIVO
- International distributor sales and support
- CE Mark and FDA-regulated medical device commercialization

## Customers

The company sells primarily to hospitals, electrophysiology labs, and clinicians treating cardiac arrhythmias, where the VIVO System is used to support pre-procedure mapping. LockeT is sold to healthcare providers and distributors serving surgical and wound-closure use cases, with the product positioned as a simple adjunct to figure-of-eight suture closure. Catheter Precision also relies on independent distributors in Europe, the UK, the Middle East, and other international markets, so channel partners are an important customer-facing layer. The customer base is shaped by regulatory approvals and clinical adoption, since both products require evidence, labeling, and market access before broad commercialization. Because the company is still building installed base and clinical awareness, repeat purchasing and distributor expansion are important to demand generation.

- **Electrophysiology physicians and EP labs** (primary) — Buy the VIVO System to help localize idiopathic ventricular arrhythmia origin sites before procedures.
- **Hospitals and surgical clinicians** (primary) — Buy LockeT for wound closure support and to help distribute suture tension over a larger area.
- **Independent medical device distributors** (secondary) — Purchase and resell products in international markets, helping the company reach customers without a large direct sales force.
- **International healthcare providers** (secondary) — Buy CE Mark-cleared products where local regulatory approval is required before commercialization.

- Electrophysiologists and EP labs buying VIVO for arrhythmia mapping
- Hospitals and clinics using LockeT for wound closure support
- Independent distributors that resell and localize market access
- International healthcare systems needing CE Mark-cleared devices
- Clinicians seeking simpler tools for suturing and wound healing

## Geography

Catheter Precision is headquartered in the United States, where it also records a majority of its sales. The company has disclosed that a meaningful share of revenue comes from customers outside the United States, with international sales varying materially by quarter. It has CE Mark clearance for the VIVO System in the EU and certain other countries, and it has begun limited sales in Europe and the UK through independent distributors. LockeT received CE Mark approval in April 2025, opening additional international commercialization opportunities, while the company also has distributor activity in the Middle East and patent protection in China. Geography matters because regulatory approvals, distributor relationships, and local market access directly determine where each product can be sold.

- United States is the core revenue base and operating center
- Europe and the UK are early international commercialization markets
- CE Mark clearance expands access across the EU and EFTA countries
- Middle East distribution agreement supports non-U.S. growth for LockeT
- China patent issuance supports longer-term IP positioning

## Strategy

Catheter Precision's near-term strategy is to convert regulatory approvals into commercial adoption for both VIVO and LockeT. The company is expanding international distribution, especially in Europe, the UK, and other CE Mark-dependent markets, because it does not have the scale of a large direct sales organization. It is also using clinical studies for LockeT to support marketing claims and potentially broaden indications for use with the FDA. In parallel, the company is protecting and repositioning intellectual property, including transferring certain VIVO-related IP to KardioNav, which may allow more focused development of assets not currently being advanced internally. The overall strategy is to extend product reach while managing limited cash resources and preserving optionality around IP and future product development.

- **Expand international commercialization** (short-term) — The company needs broader market access and distributor reach to scale sales without a large direct commercial infrastructure.
- **Support product adoption with clinical evidence** (short-term) — Clinical data helps justify use, strengthen marketing claims, and potentially expand indications with regulators and clinicians.
- **Protect and reorganize intellectual property** (medium-term) — IP ownership and patent coverage support long-term commercialization options and may create value outside the current operating plan.

- Commercialize VIVO and LockeT through regulatory clearances
- Expand distributor-led sales in Europe, the UK, and other markets
- Use clinical studies to support LockeT adoption and labeling
- Leverage CE Mark approvals to broaden addressable markets
- Manage IP through subsidiaries and targeted asset transfers
- Preserve liquidity while prioritizing commercialization spend

## Risks

Catheter Precision faces the risks typical of an early-stage medical device company: limited cash, recurring losses, and dependence on successful commercialization of a small product set. Because revenue depends on regulatory approvals and distributor execution, delays in CE Mark or FDA-related progress can slow market expansion and reduce sales momentum. The company also faces adoption risk, since clinicians must be convinced that VIVO and LockeT offer enough clinical or workflow benefit to justify purchase and use. International exposure adds regulatory, reimbursement, and channel risk, while the company’s small scale makes it vulnerable to supply chain disruptions, product quality issues, and concentration in a few products or customers. As with many medtech companies, intellectual property protection and patent enforcement are important because the products are differentiated by design and clinical utility rather than by scale.

- **Liquidity and going-concern pressure** [high] — The company has recurring operating losses and limited cash, so it may need additional financing to sustain commercialization and operations.
- **Regulatory and market-access delays** [high] — Sales depend on FDA and CE Mark clearances and on local market access, so delays can directly reduce revenue opportunities.
- **Commercial adoption risk** [medium] — Clinicians and hospitals must adopt new devices based on workflow, evidence, and reimbursement considerations, which can slow uptake.
- **Distributor concentration and execution risk** [medium] — A meaningful part of international growth relies on independent distributors, which can limit control over pricing, promotion, and inventory.
- **Product liability and quality risk** [medium] — Medical devices can face claims, recalls, or compliance issues if performance or manufacturing quality is inadequate.

- Recurring losses and low cash balance increase financing risk
- Commercial adoption may be slower than expected for new devices
- Regulatory approvals can delay or limit market expansion
- Distributor dependence can weaken control over international sales
- Small product portfolio creates concentration risk
- IP protection and patent enforcement are important to defend differentiation

## Accounting

Revenue recognition is a key accounting issue because the company sells both point-in-time products and over-time software services. VIVO and LockeT product revenue is recognized when control transfers at delivery, while VIVO software upgrade services are recognized evenly over the contract term, which can create timing differences between shipments, invoicing, and reported revenue. The company also has meaningful judgment in estimating long-lived asset impairment and useful lives, especially for acquired intangible assets and patent-related assets that may not generate immediate cash flows. Stock-based compensation, legal contingencies, income tax valuation allowances, and related-party notes can also affect reported results because the company is loss-making and capital constrained. Quarterly results may be volatile because international sales, distributor shipments, and product launch timing can shift revenue recognition from period to period.

- **Revenue recognition timing** — Reported revenue and gross margin timing
- **Long-lived asset and intangible impairment** — Operating results and balance sheet carrying values
- **Stock-based compensation** — Operating loss and diluted share count
- **Income tax valuation allowance** — Tax benefit/expense and equity

- Point-in-time revenue for VIVO and LockeT affects shipment timing
- Over-time recognition for software upgrades can smooth revenue
- Impairment testing for long-lived and intangible assets is judgmental
- Useful life estimates affect amortization expense
- Stock-based compensation and related-party items can materially affect losses
- Tax valuation allowances matter because the company has net operating losses

---

*Last updated: 2026-04-28T14:26:06.777274+00:00*